MADHAVBAUG — Vaidya Sane Ayurved Laboratories Balance Sheet
0.000.00%
- IN₹2.89bn
- IN₹2.75bn
- IN₹898.47m
- 80
- 17
- 95
- 75
Annual balance sheet for Vaidya Sane Ayurved Laboratories, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | R2022 March 31st | R2023 March 31st | R2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 9.05 | 192 | 156 | 184 | 173 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 32.3 | 45.3 | 71.2 | 73.8 | 85 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 71.9 | 255 | 278 | 314 | 303 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 171 | 172 | 201 | 230 | 214 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 258 | 500 | 549 | 697 | 767 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 139 | 125 | 129 | 116 | 112 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 160 | 141 | 144 | 141 | 142 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 97.7 | 359 | 405 | 556 | 625 |
| Total Liabilities & Shareholders' Equity | 258 | 500 | 549 | 697 | 767 |
| Total Common Shares Outstanding |